U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 21 results

Status:
US Approved Rx (2005)
First approved in 1988

Class (Stereo):
CHEMICAL (ABSOLUTE)



Octreotide (SMS 201-995, Sandostatin) is an octapeptide that exerts pharmacologic actions similar to the natural hormone, somatostatin. It was developed by Bauer and co-authors at Sandoz. It is an even more potent inhibitor of growth hormone, glucago...
Status:
US Approved Rx (2008)
First approved in 1978

Class (Stereo):
CHEMICAL (ABSOLUTE)



Bromocriptine is an ergot derivative with potent dopamine receptor agonist activity, which activates post-synaptic dopamine receptors. Bromocriptine is indicated for the treatment of dysfunctions associated with hyperprolactinemia. Bromocriptine ther...
Status:
US Approved Rx (1973)
First approved in 1957

Class (Stereo):
CHEMICAL (ABSOLUTE)



L-arginine is a nonessential amino acid that may play an important role in the treatment of cardiovascular disease due to its antiatherogenic, anti-ischemic, antiplatelet, and antithrombotic properties. It has been promoted as a growth stimulant and ...
Status:
US Approved Rx (2007)
First approved in 2007

Class:
PROTEIN


Conditions:

Lanreotide is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analog of somatostatin. It is available in several countries, including the United King...
Status:
US Approved Rx (2005)
First approved in 1988

Class (Stereo):
CHEMICAL (ABSOLUTE)



Octreotide (SMS 201-995, Sandostatin) is an octapeptide that exerts pharmacologic actions similar to the natural hormone, somatostatin. It was developed by Bauer and co-authors at Sandoz. It is an even more potent inhibitor of growth hormone, glucago...
Status:
US Approved Rx (2005)
First approved in 1988

Class (Stereo):
CHEMICAL (ABSOLUTE)



Octreotide (SMS 201-995, Sandostatin) is an octapeptide that exerts pharmacologic actions similar to the natural hormone, somatostatin. It was developed by Bauer and co-authors at Sandoz. It is an even more potent inhibitor of growth hormone, glucago...
Status:
US Approved Rx (2005)
First approved in 1988

Class (Stereo):
CHEMICAL (ABSOLUTE)



Octreotide (SMS 201-995, Sandostatin) is an octapeptide that exerts pharmacologic actions similar to the natural hormone, somatostatin. It was developed by Bauer and co-authors at Sandoz. It is an even more potent inhibitor of growth hormone, glucago...
Status:
US Approved Rx (2008)
First approved in 1978

Class (Stereo):
CHEMICAL (ABSOLUTE)



Bromocriptine is an ergot derivative with potent dopamine receptor agonist activity, which activates post-synaptic dopamine receptors. Bromocriptine is indicated for the treatment of dysfunctions associated with hyperprolactinemia. Bromocriptine ther...
Status:
US Approved Rx (1973)
First approved in 1957

Class (Stereo):
CHEMICAL (ABSOLUTE)



L-arginine is a nonessential amino acid that may play an important role in the treatment of cardiovascular disease due to its antiatherogenic, anti-ischemic, antiplatelet, and antithrombotic properties. It has been promoted as a growth stimulant and ...
Status:
US Approved Rx (1973)
First approved in 1957

Class (Stereo):
CHEMICAL (ABSOLUTE)



L-arginine is a nonessential amino acid that may play an important role in the treatment of cardiovascular disease due to its antiatherogenic, anti-ischemic, antiplatelet, and antithrombotic properties. It has been promoted as a growth stimulant and ...